|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
20
|
|
pubmed:dateCreated |
2000-7-11
|
|
pubmed:abstractText |
Mucosal immune responses are known to play important roles in the establishment of protective immunity to microbial infections through mucosa. We examined the toxic effects of recombinant cholera toxin B subunit (rCTB) secreted by Gram-positive bacterium Bacillus brevis as a mucosal adjuvant. Incubation of guinea-pig peritoneal macrophages with cholera toxin (CT) or aluminium hydroxide gel (Al-gel) released a significantly higher activity of lactate dehydrogenase than did commercial natural CTB (CTB) or rCTB. Intraintestinal or intramuscular administration of CT, CTB or Al-gel caused severe histopathological reactions. CT also caused infiltration of neutrophils and irregular arrangement or partial loss of the respiratory epithelium. In addition, CT and CTB elicited vascular permeability-increasing effects. rCTB elicited no toxic effects to macrophages and no vascular permeability-increasing effects. Moreover, it is noticeable that no distinct local histopathological reactions were observed in the nasal cavity, the small-intestinal loop or the muscle given rCTB. These results suggest that, from a safety standpoint, rCTB is a useful candidate as mucosal vaccine adjuvant.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0264-410X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
14
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2164-71
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10715532-Adjuvants, Immunologic,
pubmed-meshheading:10715532-Administration, Intranasal,
pubmed-meshheading:10715532-Aluminum Hydroxide,
pubmed-meshheading:10715532-Animals,
pubmed-meshheading:10715532-Bacillus,
pubmed-meshheading:10715532-Capillary Leak Syndrome,
pubmed-meshheading:10715532-Capillary Permeability,
pubmed-meshheading:10715532-Cells, Cultured,
pubmed-meshheading:10715532-Cholera Toxin,
pubmed-meshheading:10715532-Female,
pubmed-meshheading:10715532-Guinea Pigs,
pubmed-meshheading:10715532-Inflammation,
pubmed-meshheading:10715532-Injections,
pubmed-meshheading:10715532-Injections, Intramuscular,
pubmed-meshheading:10715532-Intestinal Mucosa,
pubmed-meshheading:10715532-Intestine, Small,
pubmed-meshheading:10715532-L-Lactate Dehydrogenase,
pubmed-meshheading:10715532-Macrophages, Peritoneal,
pubmed-meshheading:10715532-Mice,
pubmed-meshheading:10715532-Mice, Inbred BALB C,
pubmed-meshheading:10715532-Muscle, Skeletal,
pubmed-meshheading:10715532-Nasal Cavity,
pubmed-meshheading:10715532-Nasal Mucosa,
pubmed-meshheading:10715532-Peptide Fragments,
pubmed-meshheading:10715532-Rabbits,
pubmed-meshheading:10715532-Recombinant Fusion Proteins,
pubmed-meshheading:10715532-Safety
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant.
|
|
pubmed:affiliation |
Department of Safety Research on Biologics, National Institute of Infectious Diseases, Gakuen, Musashimurayama, Tokyo, Japan. ngoto@nih.go.jp
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
